New drug trial offers hope for untreatable seizure disorders
NCT ID NCT07287202
Summary
This early-stage study is testing whether an oral drug called SVG103 is safe and tolerable for adults with three rare brain conditions that cause severe, hard-to-control seizures. About 15 participants will take the drug for up to 9 months while researchers monitor for side effects and track any changes in seizure frequency. The goal is to see if this drug can help reduce seizures in people who haven't responded well to standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX (TSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Hospital
Heidelberg, Victoria, 3084, Australia
-
The Alfred
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.